These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11078501)

  • 61. The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes.
    Jakub JW; Bryant K; Huebner M; Hoskin T; Boughey JC; Reynolds C; Degnim AC
    Ann Surg Oncol; 2011 Jan; 18(1):86-93. PubMed ID: 20593241
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sentinel-node biopsy in breast cancer.
    McMasters KM
    N Engl J Med; 2003 Nov; 349(20):1968-71; author reply 1968-71. PubMed ID: 14626252
    [No Abstract]   [Full Text] [Related]  

  • 63. Management of the clinically node-negative axilla in primary and locally recurrent breast cancer.
    McGinity AC; Lautner MA; Jatoi I
    Surg Oncol Clin N Am; 2014 Jul; 23(3):463-71. PubMed ID: 24882345
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Breast cancer metastasis burden in sentinel nodes analysed using one-step nucleic acid amplification predicts axillary nodal status.
    Milner TD; de Lusignan S; Jones S; Jackson PA; Layer GT; Kissin MW; Irvine TE
    Breast; 2015 Oct; 24(5):568-75. PubMed ID: 26032111
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer.
    Jansen L; Doting MH; Rutgers EJ; de Vries J; Olmos RA; Nieweg OE
    Br J Surg; 2000 Jul; 87(7):920-5. PubMed ID: 10931029
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The positive sentinel node.
    Winchester DJ
    J Surg Oncol; 2011 Mar; 103(4):326-9. PubMed ID: 21337566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The sentinel node in invasive breast cancer. Unsolved questions and review of the national and international clinical trials].
    Rodier JF
    Cancer Radiother; 2004 Feb; 8(1):29-32. PubMed ID: 15093198
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Problems concerning patients' qualification for surgical procedures allowing for evaluation of the condition of axillary fossa lymph nodes in the radical treatment of breast cancer.
    Nowikiewicz T; Śrutek E; Zegarski W
    Pol Przegl Chir; 2015 Jun; 87(6):290-4. PubMed ID: 26247499
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical significance of minimal sentinel node involvement and management options.
    Chagpar AB
    Surg Oncol Clin N Am; 2010 Jul; 19(3):493-505. PubMed ID: 20620923
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Sentinel lymph node biopsy in breast carcinoma. Can removal of the sentinel node replace axillary dissection?].
    Schalhorn B
    Fortschr Med; 1999 Feb; 117(5):22. PubMed ID: 10095307
    [No Abstract]   [Full Text] [Related]  

  • 71. [Axillary dissection].
    Delaloye JF; Irion O
    Rev Med Suisse; 2013 Oct; 9(403):1931. PubMed ID: 24245013
    [No Abstract]   [Full Text] [Related]  

  • 72. Sentinel node biopsy and improved patient care.
    Giuliano AE; Gangi A
    Breast J; 2015; 21(1):27-31. PubMed ID: 25546431
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
    Noguchi M
    Eur J Surg Oncol; 2008 Feb; 34(2):129-34. PubMed ID: 17498911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
    Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial.
    Caudle AS; Hunt KK; Kuerer HM; Meric-Bernstam F; Lucci A; Bedrosian I; Babiera GV; Hwang RF; Ross MI; Feig BW; Hoffman K; Litton JK; Sahin AA; Yang W; Hortobagyi GN; Buchholz TA; Mittendorf EA
    Ann Surg Oncol; 2011 Sep; 18(9):2407-12. PubMed ID: 21327455
    [No Abstract]   [Full Text] [Related]  

  • 76. Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial.
    Caudle AS; Hunt KK; Mittendorf EA
    Ann Surg Oncol; 2011 Dec; 18 Suppl 3():S283. PubMed ID: 21725683
    [No Abstract]   [Full Text] [Related]  

  • 77. ASO Author Reflections: Completion Axillary Dissection Can Be Avoided but Inconsistent Trial Design Complicates Choosing Between Alternative Strategies.
    Castelo M; Scheer AS
    Ann Surg Oncol; 2020 Aug; 27(8):2677-2678. PubMed ID: 32206953
    [No Abstract]   [Full Text] [Related]  

  • 78. Optimizing Surgical Management of the Axilla After Neoadjuvant Chemotherapy: An Evolving Story.
    Mamounas EP
    Ann Surg Oncol; 2018 Aug; 25(8):2124-2126. PubMed ID: 29850953
    [No Abstract]   [Full Text] [Related]  

  • 79. Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    Mittendorf EA; King TA; Tolaney SM
    J Clin Oncol; 2022 Oct; 40(29):3361-3364. PubMed ID: 35675571
    [No Abstract]   [Full Text] [Related]  

  • 80. Patterns of care with a positive sentinel node: echoes of an opportunity missed.
    Morrow M
    Ann Surg Oncol; 2009 Sep; 16(9):2429-30. PubMed ID: 19585172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.